Popat S, et al. A multicenter randomized phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma (MPM) – results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-MESO trial. ESMO Congress 2019, abstract LBA91_PR.
EULAR-adviezen over reumatische bijwerkingen van immuuntherapie
mei 2020 | Immuuntherapie